Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
Description: Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, is focused on the discovery, development, and commercialization of first-in-class glaucoma therapies. Its lead product candidate, Rhopressa, is a once-daily triple-action eye drop, which demonstrated the ability to reduce intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension in a Phase 2b clinical trial. The company is conducting two Phase 3 registration trials in the U.S. to demonstrate non-inferiority of IOP lowering for Rhopressa compared to timolol, as well as commencing a third safety-only Phase 3 registration trial of Rhopressa in Canada. It also develops once-daily quadruple-action Roclatan, a single drop combination of Rhopressa with latanoprost, which has completed a 28-day Phase 2b clinical trial. In addition, the company is taking preparatory steps for Phase 3 registration trials for Roclatan. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Bedminster, New Jersey.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-3.31||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E||-15.12|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-30.07%||ROE||-120.74%||ROI|
|Current Ratio||7.63||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.46|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||35.07 M||Cash From Investing Activities||6.1 M||Cash From Operating Activities||-13.31 M||Gross Profit|
|Net Profit||-17.24 M||Operating Profit||-19.64 M||Total Assets||195.2 M||Total Current Assets||170.96 M|
|Total Current Liabilities||22.39 M||Total Debt||124.19 M||Total Liabilities||146.58 M||Total Revenue|
|High 52 week||68.7||Low 52 week||21.26||Last close||23.52||Last change||2.62%|
|RSI||57.25||Average true range||1.27||Beta||1.37||Volume||623.98 K|
|Simple moving average 20 days||4.02%||Simple moving average 50 days||-14.83%||Simple moving average 200 days||-40.08%|
|Performance Week||8.94%||Performance Month||-6.11%||Performance Quart||-45.33%||Performance Half||-41.77%|
|Performance Year||-63.68%||Performance Year-to-date||-34.85%||Volatility daily||2.95%||Volatility weekly||6.59%|
|Volatility monthly||13.51%||Volatility yearly||46.81%||Relative Volume||235.1%||Average Volume||767.44 K|
|New High||New Low|
2019-09-16 11:46:52 | Weekly CEO Buys Highlight
2019-09-10 21:36:00 | Aerie Pharmaceuticals Announces Full Exercise by Initial Purchasers of Option to Purchase Additional $41.25 Million Aggregate Principal Amount of Aerie’s 1.50% Convertible Senior Notes Due 2024
2019-09-09 19:15:04 | Aerie Pharmaceuticals Inc AERI CEO Vicente Jr Anido Bought $499,012 of Shares
2019-09-09 06:00:00 | These 2 Biotech Stocks Are Seeing Insider Buying Activity
2019-09-06 14:42:00 | Durham pharma embarks on $275M financial trade
2019-09-06 09:31:01 | Aerie AERI Down 19.7% Since Last Earnings Report: Can It Rebound?
2019-09-03 16:01:00 | Aerie Pharmaceuticals to Offer $250 Million Convertible Senior Notes Due 2024
2019-08-20 06:30:00 | Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
2019-08-19 13:56:47 | Zuckerberg Sells Shares of Facebook
2019-08-08 16:08:47 | This Biotech Crashed On 'Erroneous' Report — Plus 2 Stocks That Diverged
2019-08-08 09:25:01 | Aerie AERI Beats on Q2 Earnings & Sales, Lowers Guidance
2019-08-08 09:02:35 | Aerie Pharmaceuticals, Inc.'s NASDAQ:AERI Path To Profitability
2019-08-08 04:05:55 | Edited Transcript of AERI earnings conference call or presentation 7-Aug-19 9:00pm GMT
2019-08-08 01:50:14 | Aerie Pharmaceuticals, Inc. AERI Q2 2019 Earnings Call Transcript
2019-08-07 18:05:10 | Aerie Pharmaceuticals AERI Reports Q2 Loss, Tops Revenue Estimates
2019-07-31 10:36:02 | Will Aerie Pharmaceuticals AERI Report Negative Earnings Next Week? What You Should Know
2019-07-28 21:23:28 | Analysts Recommend Buying These 2 Falling Knives
2019-07-18 18:26:10 | Allergan Announces FDA Acceptance of Glaucoma Candidate NDA
2019-07-18 08:22:21 | Hatteras Ventures-backed firm adds fresh round of capital
2019-07-11 06:46:00 | How a Durham firm stands to benefit from an unexpected break in a Japanese trial
2019-07-09 17:48:09 | Aerie Completes Enrollment Under Rhopressa Study in Japan
2019-06-24 08:50:12 | Ocular OCUL Gets FDA Nod for Label Expansion of Dextenza
2019-06-20 19:09:44 | Is Aerie Pharmaceuticals Inc AERI A Good Stock To Buy?
2019-06-18 08:05:56 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2019-06-13 08:03:28 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2019-06-11 08:04:17 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2019-06-11 07:30:00 | Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences
2019-06-10 08:05:36 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2019-06-06 13:58:01 | Does Aerie Pharmaceuticals, Inc. NASDAQ:AERI Have A Particularly Volatile Share Price?
2019-06-06 09:31:01 | Why Is Aerie AERI Down 10.2% Since Last Earnings Report?
2019-06-06 08:06:55 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2019-05-28 07:30:00 | Aerie Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference
2019-05-21 17:36:09 | Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint
2019-05-08 14:45:06 | Aerie AERI Q1 Earnings Beat, Rhopressa Misses Estimates
2019-05-08 00:02:38 | Edited Transcript of AERI earnings conference call or presentation 7-May-19 9:00pm GMT
2019-05-07 22:46:35 | Aerie Pharmaceuticals, Inc. AERI Q1 2019 Earnings Call Transcript
2019-05-07 18:15:10 | Aerie Pharmaceuticals AERI Reports Q1 Loss, Lags Revenue Estimates
2019-05-07 17:09:37 | Aerie: 1Q Earnings Snapshot
2019-05-07 08:05:55 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2019-05-03 14:42:30 | Another $100 million 'safety net' set for this Triangle pharma
2019-05-02 12:42:44 | Here’s What Hedge Funds Think About Aerie Pharmaceuticals Inc AERI